Cisplatin Drug Profile | PharmaGraphX

Boxed warning

Cumulative nephrotoxicity — adequate hydration required
Ototoxicity
Anaphylactic reactions
Myelosuppression

Clinical alerts

Boxed warning

4 boxed warnings

Narrow therapeutic index

Small dose changes can cause toxicity or loss of effect

Nephrotoxic

Monitor renal function; avoid other nephrotoxins where possible

Mechanism of action

Forms intrastrand and interstrand DNA crosslinks, inhibiting DNA replication

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Stage II Nasopharyngeal Carcinoma AJCC v8
·Stage III Nasopharyngeal Carcinoma AJCC v8
·Stage IV Nasopharyngeal Carcinoma AJCC v8
·Limited Stage Lung Small Cell Carcinoma
·Stage I Lung Cancer AJCC v8

Interactions

No curated interaction pairs are recorded for Cisplatin. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Severe nausea/vomiting
Nephrotoxicity
Ototoxicity
Myelosuppression

Food, alcohol & herbal

Alcohol · minor

No significant interaction

Pharmacokinetics

Half-life: 20-30 minutes (distribution); 58-73 hours (terminal)
Protein binding: 90%

Pregnancy & lactation

Not recorded for Cisplatin. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database.